Application of biomarker in colorectal cancer

• Main Authors: HE WENTING, ZHANG HONGLIANG, ZENG FANYE, CHI JIEJUN, FU XIAOLE, JIE YANGHUA, ZHU YANHUA, YANG XIAOBEI, ZHOU YUKUN
• Format: Patent
• Language: Chinese; English
• Published: 05.09.2017
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; TESTING; VINEGAR; WINE

The invention discloses an application of a biomarker in colorectal cancer. The biomarker is NHEG1 concretely. The expression down-regulation of the NHEG1 in spleen qi deficiency type advanced colorectal cancer patients is found for the first time, so the expression level of the NHEG1 becomes the basis for judgment of the typing of the advanced colorectal cancer patients. The invention also provides an application of an NHEG1 gene in the treatment effect evaluation of the spleen qi deficiency type advanced colorectal cancer patient. When the expression level of the NHEG1 in the spleen qi deficiency type advanced colorectal cancer patients is not obviously different from the expression level of the NHEG1 in non-spleen qi deficiency type advanced colorectal cancer patients, the treatment effect of a medicine is good. 本发明公开了生物标志物在结直肠癌中的应用，具体地该生物标志物为NHEG1，本发明首次发现了NHEG1在脾气亏虚型晚期结直肠癌患者中表达下调，提示检测NHEG1的表达水平可以成为判断晚期结直肠癌患者分型的依据。同时，本发明提供了NHEG1基因在制备脾气亏虚型晚期结直肠癌患者疗效评价中的应用，当脾气亏虚型晚期结直肠癌患者中NHEG1的表达水平与非脾气亏虚型晚期结直肠癌患者中的表达水平无明显差异时